Objectives: To determine the phenotypic and molecular characteristics of Neisseria gonorrhoeae isolates obtained between 2006 and 2012 in Slovenia.
Introduction
Gonorrhoea remains a sexually transmitted infection (STI) of major public health importance. The WHO estimated that 106 million new cases of gonorrhoea occurred among adults worldwide in 2008, which was a marked increase (21%) in the estimated global incidence compared with 2005. Gonorrhoea, including its severe complications, results in substantial morbidity and economic costs globally. The annual incidence of gonorrhoea in the WHO European region (53 countries) was estimated to be 3.4 million cases. 1 However, the reported incidence of gonorrhoea in the European Union (EU) and European Economic Area (EEA) has been substantially lower, e.g. 39 179 cases (incidence: 12.6 per 100 000 inhabitants) of gonorrhoea were reported in the 30 EU/EEA countries in 2011. 2 This might indicate suboptimal diagnosis and/or incomplete case reporting and epidemiological surveillance of gonorrhoea in many EU/EEA countries. In Slovenia, the reported incidence of gonorrhoea showed a peak in the early 1970s, with 2600 new cases (incidence: 151.2 per 100000 inhabitants) annually, and has since fallen to only 25 new cases in 2011 (incidence: 1.2 per 100 000 inhabitants). 2, 3 In the absence of a vaccine, appropriate prevention, effective diagnostics and particularly antimicrobial treatment are essential to control the spread of gonorrhoea in communities and to mitigate the serious sequelae of the infection in individual cases. However, Neisseria gonorrhoeae has in recent decades developed resistance to all antimicrobial agents that have been introduced as first-line treatment for the infection, including most recently the last remaining option for first-line monotherapy, namely the extended-spectrum cephalosporins (ESCs), which might seriously compromise the future infection control of gonorrhoea. 4, 5 Many verified treatment failures with cefixime (oral ESC) 6 -13 and some also using ceftriaxone (parenteral ESC) 14 -19 have been recently reported from many areas worldwide. Furthermore, in recent years the first extensively drug-resistant (XDR) 4 N. gonorrhoeae isolates, including high-level ceftriaxone resistance, were described. 9, 18, 20 This alerted several healthcare-governing organizations to react and try to mitigate the emergence and spread of ESC-resistant and difficult-to-treat gonorrhoea, including its severe consequences. 21 -23 One of the main focuses of those published action or response plans was to strengthen the surveillance of gonorrhoea and antimicrobial resistance in N. gonorrhoeae, both at national and at international levels. Enhanced capacity of gonococcal culture and performance of antimicrobial susceptibility testing with relevant antimicrobial agents are issues of highest priority. Other priorities include the need to ensure guidelines are evidence based and the establishment of surveillance systems for the monitoring and verification of treatment failures. 21, 22 There is also an ongoing need to fully elucidate the genetic basis for ESC resistance in order to facilitate the development of molecular tests. Mutations in the penA gene encoding the penicillin-binding protein 2 (PBP2) are the main determinant for decreased susceptibility and resistance to ESCs. The acquisition of specific penA mosaic genes or an alteration of amino acid A501 in PBP2 result in a lower affinity for ESCs and an associated decrease in ESC susceptibility. 5,9,18,24 -29 In addition, specific mutations in the promoter or coding sequence of the repressor gene mtrR cause an overexpression of the MtrCDE efflux pump system that exports ESCs out of the cell (mtrR resistance determinant), which further decreases ESC susceptibility. 5,9,18,25,29 -31 Alterations of amino acids G101 and A102 in PorB1b result in decreased permeability and further decreased susceptibility to ESCs (penB resistance determinants). 5, 9, 18, 25, 29, 32, 33 There is still at least one unknown non-transformable ESC resistance determinant. 5, 9, 18, 29 For molecular epidemiological typing of gonococci, N. gonorrhoeae multiantigen sequence typing (NG-MAST) has been used in many countries. 34 The aims of this study were to phenotypically and genetically characterize N. gonorrhoeae isolates from Slovenia in 2006-12, to elucidate the molecular epidemiology of the emergence and spread of N. gonorrhoeae with decreased susceptibility and resistance to ESCs in Slovenia.
Materials and methods
The work was performed at the WHO Collaborating Centre for Gonorrhoea and other STIs, National Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Microbiology, Ö rebro University Hospital, SE-701 85 Ö rebro, Sweden.
N. gonorrhoeae isolates
One hundred and ninety-four isolates (obtained from 74% of the gonorrhoea cases reported in Slovenia between 2006 and 2012) 35 were studied. All 194 isolates were sent to the WHO Collaborating Centre for Gonorrhoea and other STIs, Ö rebro University Hospital, Sweden for further analysis: species confirmation by culture on selective agar media, a sugar utilization test and the PhadeBact Monoclonal GC Test (Bactus AB, Solna, Sweden); antimicrobial susceptibility testing; and molecular characterization. All N. gonorrhoeae isolates were preserved at 2708C. The 2008 WHO N. gonorrhoeae reference strains 36 were used for quality control of all phenotypic and molecular characterizations.
Phenotypic antimicrobial susceptibility testing
The MICs (mg/L) of eight antimicrobials (cefixime, ceftriaxone, penicillin, ciprofloxacin, azithromycin, tetracycline, gentamicin and spectinomycin) were determined using the Etest method (bioMé rieux, AB, Solna, Sweden) in accordance with the manufacturer's instructions. The MIC values were interpreted in accordance with EUCAST clinical breakpoint criteria V3.1. 37 However, no breakpoints for gentamicin have yet been stated by any organization. Furthermore, gonococcal isolates with an ESC MIC of only 0.125 mg/L have resulted in treatment failures with ESCs 6,13 -15 and, accordingly, in the present study in vitro decreased susceptibility to cefixime and ceftriaxone was defined as having an MIC of .0.064-0.125 mg/L. b-Lactamase production was identified using nitrocefin solution.
Isolation of genomic DNA
Bacterial DNA was isolated with the NorDiag Bullet instrument (NorDiag ASA Company, Oslo, Norway) using the Bugs'n Beads STI-fast kit (NorDiag ASA Company), in accordance with the manufacturer's instructions, and preserved at 2208C prior to further analysis.
Molecular epidemiological typing
NG-MAST was performed on all isolates as previously described. 36 Briefly, this method compares nucleotide sequences of two hypervariable domains of two genes, porB and tbpB. Allele types and sequence types (STs) were assigned using the NG-MAST database (www.ng-mast.net). Closely related STs were clustered using previously described genogroup definition. 38, 39 Accordingly, STs that shared one identical allele with the other allele showing ≥99% identity, were clustered together in a genogroup, which was named after the predominant ST within the specific genogroup.
ESC resistance determinant genotyping
ESC resistance determinant genotyping was performed as previously described. Briefly, the presence of specific alterations in PBP2 was screened using real-time PCR followed by pyrosequencing to identify penA mosaic alleles, PBP2 A501 alterations and the D345a insertion, as previously described. 40 Further characterization of all penA mosaic alleles and A501-altered penA alleles was performed by conventional Sanger sequencing of the penA gene and subsequent alignment with previously described penA allele sequences. 18, 36, 41 Polymorphisms in the promoter and coding region of the mtrR gene and in the porB1b gene (amino acid position G101/A102 of the encoded PBP2) were identified using sequencing as previously described. 36, 41 Sequence editing and multiple sequence alignments were performed using the software CLC Main Workbench 6.8.1.
Results

Gonorrhoea patients and N. gonorrhoeae isolates
The majority (n ¼ 182; 94%) of the available isolates were from the Institute of Microbiology and Immunology, Medical Faculty, University of Ljubljana and only 6% (n ¼ 12) were from other Slovenian laboratories. Of the isolates, 95% (n ¼ 185) were from males (median age: 27 years; mean age: 31 years; range: 16 -63 years) and only 5% (n¼ 9) were from female patients (median age: 27 years; mean age: 29 years; range: 16 -32 years). Eighty percent (n ¼ 156) of the isolates were cultured from urogenital specimens (urethra/cervix), 11% (n ¼ 22) from anorectal specimens, 8% (n ¼ 15) from pharyngeal specimens and 0.5% (n ¼ 1) from joint fluid from a patient with gonococcal septic hip arthritis. The mode of transmission was known for 89% (n ¼ 172) of the patients, of which 49% (n¼ 84) were infected through heterosexual contact and 51% (n¼ 88) were transmitted among men who have sex with men (MSM).
Antimicrobial susceptibility of Slovenian N. gonorrhoeae isolates (n 5 194)
Overall, the proportions of N. gonorrhoeae isolates showing in vitro resistance (decreased susceptibility) were as follows: tetracycline, 48% (24%); ciprofloxacin, 46% (0%); penicillin, 37% (59%); azithromycin, 11% (28%); cefixime, 1.5% (9.8%); ceftriaxone, 0% (5.2%); and spectinomycin, 0% (0%). No breakpoint for gentamicin exists; however, the MIC values of gentamicin for the isolates were generally low with unimodal MIC distribution (modal MIC: 4 mg/L; MIC range: 0.5 -16 mg/L). b-Lactamase production was detected in 12% of the isolates. There were no significant differences in the MICs of any antimicrobials for the urogenital isolates compared with the extragenital isolates (mainly from rectum and pharynx). Table 1 presents longitudinal trends (2006 -12) in the decreased susceptibility or resistance to antimicrobials selected due to their higher relevance with regard to treatment: cefixime, ceftriaxone, ciprofloxacin and azithromycin.
Briefly, decreased susceptibility or resistance to cefixime (defined as MIC ≥0.125 mg/L) was first detected in 2008 (one isolate; 4%) and then significantly increased to 33% (six isolates) in 2011 (P,0.01), followed by a subsequent steep decrease in 2012 with only 6% (three isolates) of isolates showing decreased susceptibility or resistance to cefixime (P,0.005). A similar, albeit less pronounced, epidemic curve was also noted for the decreased susceptibility or resistance to ceftriaxone (defined as MIC ≥0.125 mg/L), with the introduction of those strains in 2009 (two isolates; 10%), an increase in 2010 (four isolates; 15%) and then a gradual decrease in the following years, reaching the lowest value in 2012 (two isolates; 4%). Bimodal MIC distributions for cefixime and ceftriaxone were indicated, with two peaks at ,0.016 and 0.125 mg/L for cefixime and 0.004 and 0.032 mg/L for ceftriaxone, respectively, indicating the existence of at least two discrete strain populations with different ESC susceptibility profiles. Regarding ciprofloxacin, in Slovenia, resistance (defined as MIC . 
Molecular epidemiology characterization of Slovenian N. gonorrhoeae isolates (n 5194)
Among the 194 isolates investigated, 78 different NG-MAST STs were identified, representing 68 porB alleles and 32 tbpB alleles. Twenty-two (28%) of those STs had not been previously described. In total, 31 STs were represented by more than one isolate and 47 STs had only one representative. The most prevalent STs that were represented by at least five isolates were ST1407 (9% of all isolates), ST21 (6%), ST225 (6%), ST4 (5%), ST2675 (4%), ST5615 (4%), ST8464 (3%), ST1195 (3%), ST2992 (3%), ST5340 (3%) and ST5570 (3%). With further clustering of closely related STs, seven predominant genogroups were identified, namely G1407, G21, G1195, G4, G2675, G2992 and G225, which cumulatively represented 97 (50%) isolates. The annual distribution of those seven predominant genogroups is summarized in Figure 2 . Briefly, during 2006 and 2007, genogroups that shared the tbpB allele 4, namely G4, G225 and G2675, were predominant (43% and 36% of all isolates in 2006 and 2007, respectively). Those genogroups were subsequently replaced in 2008 by G1195, G8653, ST8063 and ST995 (sharing the tbpB allele 29) isolates that cumulatively represented 44% of all isolates that year. G1407 (tbpB allele 110) was introduced in Slovenia in 2008 and became the predominant genogroup for the next three consecutive years: 2009, 48% of all isolates (43% were ST1407); 2010, 30% (15% ST1407); and 2011, 28% (11% ST1407). However, it was largely replaced in 2012 (8%; 50% ST1407) by particularly the genogroup G21 (tbpB allele 33), but also G1195 and G2992 (tbpB allele 29). Isolates from all those genogroups were frequent also before the expansion of isolates belonging to G1407.
The phenotypic, genotypic and basic demographic/epidemiological characterization of the seven most common Slovenian N. gonorrhoeae genogroups is summarized in Table 2 .
Briefly, the G1407 isolates [n¼ 28; of which 18 isolates (64%) were ST1407] accounted for nearly all the decreased susceptibility or resistance to cefixime (95%) and ceftriaxone (100%) during 2008 -12 and had modal MIC ¼ 0.125 mg/L (range: 0.032 -0.25 mg/L) and MIC ¼ 0.064 mg/L (range: 0.032 -0.125 mg/L) of cefixime and ceftriaxone, respectively. All those G1407 isolates were also ciprofloxacin resistant (MIC ≥32 mg/L) and 71% had a decreased susceptibility or resistance to azithromycin (modal MIC: 0.5 mg/L; range: 0.125 -8 mg/L) (P value ,0.001 for both). Twenty-six (93%) of the G1407 isolates were obtained from males, of which 18 (69%) were known to be from MSM (P,0.05). Furthermore, of the 28 G1407 isolates, 7 were isolated from rectum (representing 32% of all rectal isolates) and 5 from pharynx (representing 33% of all pharyngeal isolates). However, in 2012 when genogroup G1407 was largely replaced by particularly G21, but also G1195 and G2992, the levels of decreased susceptibility or resistance to ESCs and resistance to ciprofloxacin significantly decreased.
ESC resistance determinants in Slovenian N. gonorrhoeae isolates (n 5 194)
Among all 194 isolates investigated, 20% (n ¼ 39) contained a penA mosaic allele. Thirty-four (87%) of those isolates contained the penA mosaic allele XXXIV. 5, 18 Accordingly, all G1407 isolates (n ¼ 28), but also some isolates of ST2569, ST2970 (n ¼ 2), ST5607 and ST5614 (n ¼ 2), contained the penA mosaic XXXIV. The MICs of cefixime and ceftriaxone for the isolates with penA mosaic allele XXXIV ranged from 0.032 to 0.25 mg/L (modal MIC: 0.125 mg/L) and from 0.008 to 0.125 mg/L (modal MIC: 0.064 mg/L), respectively. Two isolates (1%) contained an alteration of A501 in PBP2. Accordingly, one isolate had an A501V alteration and one isolate an A501T alteration; both isolates had an elevated MIC of cefixime (0.032 and 0.064 mg/L, respectively) and ceftriaxone (0.064 and 0.032 mg/L, respectively). An aspartate insertion at amino acid position 345 of PBP2 (D345a), indicating decreased susceptibility or resistance to penicillin, was present in 76% (n ¼ 147) of all isolates. Wild-type PBP2 sequence was present in only 4% (n ¼ 7) of the isolates, all of which had low MICs of cefixime and ceftriaxone (,0.016 and ,0.002 mg/L, respectively).
A single nucleotide (A) deletion in the promoter region of the mtrR gene and an alteration in the coding sequence of the MtrR (G45D), which cause overexpression of the MtrCDE efflux pump (mtrR resistance determinant), were present in 48% (n¼ 94) and 21% (n ¼ 40) of the isolates, respectively. Sixty-two percent (n ¼ 120) of the isolates contained at least one of those mtrR alterations and 7% (n ¼ 14) contained simultaneously both alterations. Alterations in amino acid residues G101 and/or A102 of PorB1b, which result in decreased influx of antimicrobials through the outer membrane protein PorB1b (penB resistance determinant), were present in 65% (n ¼ 127) of the isolates. penB genotypes KD (K101/D102), KN (K101/N102) and GS (G101/S102) were predominant and were present in 28% (n ¼ 54), 15% (n ¼ 29) and 10% (n ¼ 19) of the isolates, respectively. Genotype KD was associated with genogroups G21, G225 and G2992, while genotypes KN and GS were associated with G1407 and G1195, respectively. penB and mtrR resistance determinants are interdependent, act synergistically and were simultaneously present in 49% (n¼ 95) of the isolates.
Discussion
The present study shows that the antimicrobial resistance of N. gonorrhoeae isolates in Slovenia is high and decreased susceptibility and resistance to antimicrobials previously and currently recommended for treatment of gonorrhoea has evolved rapidly during the latest 5 -10 years. It was also elucidated that the longitudinal fluctuations in the cumulative resistance rates to several antimicrobial agents were mainly due to the spread of several discrete clones (NG-MAST STs/genogroups) of resistant gonococci in the population. Fortunately, the multidrug-resistant G1407 clone, which accounted for nearly all the decreased susceptibility or resistance to ESCs, appeared to be largely replaced by some ESC-and ciprofloxacin-susceptible clones, such as G21, G1195 and G2992, in 2012. Consequently, in 2012 the levels of decreased susceptibility or resistance to ESCs and resistance to ciprofloxacin among N. gonorrhoeae isolates in Slovenia significantly decreased.
The evolution and international spread of ESC resistance among gonococci during the recent 5 -10 years is exceedingly worrying, because the infection control of gonorrhoea relies entirely on prevention, effective diagnostics and particularly appropriate first-line empirical antimicrobial therapy, which is based on adequate antimicrobial susceptibility surveillance and enhanced by recommendations provided by national and international organizations. When resistance to a specific antimicrobial agent reaches a threshold of 5% in a specific population, it is recommended to replace that antimicrobial as a first-line empirical treatment option. 21 However, due to the international spread of resistance to ESCs and lack of an appropriate alternative to ESCs for antimicrobial monotherapy, dual antimicrobial therapy with parenteral ESC (ceftriaxone; 250 -500 mg) together with particularly azithromycin (1 -2 g) has been recently recommended in the USA and Europe. 42 -44 The present study clearly illustrates that the rapid increase in decreased susceptibility or resistance to ESCs and resistance to ciprofloxacin among gonococcal isolates in Slovenia was due to the spread of the G1407 clone. Furthermore, the decreased susceptibility or resistance to ESCs in the G1407 isolates was due to the penA mosaic allele XXXIV (found in all G1407 isolates), but also to the additional ESC resistance determinants; all of the G1407 isolates had an A-deletion in the mtrR promoter and 26 (93) 16 (100) 15 (100) 12 (92) 8 (89) 8 (100) 8 (100) female, n (%) 2 (7) 
K101/N102 alterations in PorB1b. The G1407 clone has reached mainly epidemic proportions in many European countries and globally during the latest 5 -10 years and accounted for most of the decreased susceptibility or resistance to ESCs in many countries. It has also been responsible for the majority of the verified cefixime and ceftriaxone treatment failures, including a recent treatment failure of pharyngeal gonorrhoea with ceftriaxone in Slovenia. 5,9 -15,20,38,39,45 -48 Furthermore, also the two gonococcal XDR strains isolated in France and Spain belonged to the G1407 clone (ST1407). However, those strains additionally showed a high-level resistance to ceftriaxone, due to a single additional mutation in their penA mosaic allele XXXIV resulting in an A501P alteration in PBP2. 9, 20 In the present study, it was also shown that the spread of the G1407 clone in Slovenia was very swift. The G1407 isolates first emerged in Slovenia in 2008 and already in 2009 those isolates accounted for nearly half (48%) of all the gonococcal isolates. However, the prevalence of G1407 isolates then slowly declined in the following years to reach 8% in 2012. A similar decline in the prevalence of gonococcal isolates with decreased susceptibility to cefixime, from 17% in 2010 to 11% in 2011, was recently described from England and Wales where the G1407 clone accounted for 91% of the isolates with decreased susceptibility to cefixime. 38 The authors speculated that the decline could be due to the quick adoption of altered treatment recommendations with a decrease in cefiximebased therapy (switched to ceftriaxone), dropping from 50% in 2010 to 5% in 2011. This altered treatment might at least partly explain the decline in the prevalence of isolates with decreased susceptibility and resistance to ESCs. However, the decline has been very rapid and similar declines have been observed since 2009 -10 in also some other European countries, 49 many of which still use cefixime relatively frequently and that have not strictly implemented the dual antimicrobial therapy with ceftriaxone and azithromycin recommended in the revised European guidelines. 44 Accordingly, the decreased prevalence of isolates with decreased susceptibility and resistance to ESCs might also be affected by 'epidemiological replacement' (out-competing) of the multidrug-resistant G1407 clone by more ESC-susceptible gonococcal clones. This issue and the effect on the distribution of other genogroups was not possible to determine in the UK study, since NG-MAST was performed only on isolates with a decreased susceptibility to cefixime. 38 Unfortunately, the knowledge regarding natural epidemiological curves and replacement of gonococcal clones remains limited. It would be exceedingly valuable to perform molecular typing of the entire gonococcal population in all the countries displaying a decline in the decreased susceptibility and resistance to ESCs, to elucidate if the observed increased ESC susceptibility in those countries is also due to a replacement of the G1407 clone by more ESC-susceptible gonococcal clones. In the present study, as well as in several previous studies, G1407 was strongly associated with the MSM population; however, in the present study, 25% of the G1407 infections were among heterosexuals (five males and two females), illustrating that G1407 is spreading in the heterosexual population as well. 38, 39 An interesting finding in the present study was that in 2012 the multidrug-resistant G1407 clone, which accounted for nearly all the decreased susceptibility or resistance to ESCs, appeared to be largely replaced by some ESC-and ciprofloxacin-susceptible clones, such as G21, G1195 and G2992. This resulted in a Evolution of resistance in N. gonorrhoeae in Slovenia 1523 JAC significant decline in the levels of decreased susceptibility or resistance to ESCs and resistance to ciprofloxacin among N. gonorrhoeae isolates in Slovenia in 2012. The predominating genogroup in 2012, namely G21 (26% of all isolates), was present in Slovenia already in 2007 and 2008; however, it was not identified during 2009 -11. The G21 isolates were susceptible to ESCs and ciprofloxacin (P, 0.001); however, worryingly, this genogroup was significantly associated with decreased susceptibility or resistance to azithromycin (modal MIC: 1 mg/L) (P, 0.001). Although the majority of the G21 isolates were from MSM, the association with this high-risk group did not reach statistical significance (P¼ 0.139).
The main limitation of the present study was the low number of N. gonorrhoeae isolates per year. However, the investigated isolates still represented 74% of all reported gonorrhoea cases from 2006 to 2012 in Slovenia.
In conclusion, the prevalence of decreased susceptibility or resistance to previously or currently recommended antimicrobials, including ESCs, for the treatment of gonorrhoea in Slovenia has been high during recent years. However, the resistance prevalence has fluctuated rapidly over time, mainly due to the longitudinal prevalence of a few gonococcal clones. Fortunately, in 2012 some gonococcal clones susceptible to ESCs and ciprofloxacin, such as G21, G1195 and G2992, appeared to have replaced the multidrug-resistant G1407 clone. This type of 'epidemiological clone replacement' might be indicated in several European countries, which would be valuable to investigate further. The decline of the G1407 isolates in Slovenia might also, at least partly, be affected by an appropriate implementation of the revised European gonorrhoea guidelines, 44 in Slovenia, recommending dual therapy with ceftriaxone (500 mg) together with azithromycin (2 g) in addition to mandatory test of cure. In Slovenia, as well as internationally, strict adherence to evidencebased treatment guidelines and longitudinal antimicrobial susceptibility surveillance, ideally combined with molecular epidemiological characterization of the gonococcal isolates and surveillance of treatment failures, remain essential. Ultimately, novel antimicrobials are crucial for the future treatment of gonorrhoea.
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